Huya Bioscience International, of San Diego, said Shenzhen Chipscreen Biosciences Ltd., of Shenzhen, China, has received marketing approval for its oral HDAC inhibitor, HBI-8000 (chidamide), for relapsed or refractory peripheral T-cell lymphoma, from the CFDA.